At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
PROK ProKidney Corp.
Trading 12-18 13:38:30 EST
2.38
+0.03
+1.28%
High2.54Low2.35Vol951.29K
Open2.39D1 Closing2.35Amplitude8.30%
Mkt Cap716.02MTradable Cap652.53MTotal Shares300.83M
T/O2.32MT/O Rate0.35%Tradable Shares274.16M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

HC Wainwright Initiates Coverage on ProKidney With Buy Rating, $12 Price Target
MT Newswires Live  ·  12-16 20:38
HC Wainwright Initiates Coverage on ProKidney With Buy Rating, $12 Price Target
ProKidney Initiated at Buy by HC Wainwright & Co.
Dow Jones  ·  12-16 20:13
ProKidney Initiated at Buy by HC Wainwright & Co.
ProKidney Corp. : H.c. Wainwright Initiates Coverage With Buy Rating
THOMSON REUTERS  ·  12-16 19:09
ProKidney Corp. : H.c. Wainwright Initiates Coverage With Buy Rating
ProKidney Corp. Director Brian JG Pereira Reports Sale of Common Shares
Reuters  ·  11-15
ProKidney Corp. Director Brian JG Pereira Reports Sale of Common Shares
ProKidney Q3 EPS $(0.12) Beats $(0.14) Estimate, Sales $217.000K Beat $44.250K Estimate
Benzinga  ·  11-11
ProKidney Q3 EPS $(0.12) Beats $(0.14) Estimate, Sales $217.000K Beat $44.250K Estimate
ProKidney reports Q3 2025 results and updates on Phase 3 CKD therapy trial
Reuters  ·  11-11
ProKidney reports Q3 2025 results and updates on Phase 3 CKD therapy trial
ProKidney: Q3 Net Loss per Share Attributable to Class a Stock $0.12
THOMSON REUTERS  ·  11-11
ProKidney: Q3 Net Loss per Share Attributable to Class a Stock $0.12
Press Release: ProKidney Reports Third Quarter 2025 Financial Results and Provides Regulatory and Clinical Updates
Dow Jones  ·  11-11
Press Release: ProKidney Reports Third Quarter 2025 Financial Results and Provides Regulatory and Clinical Updates
Prokidney Corp expected to post a loss of 13 cents a share - Earnings Preview
Reuters  ·  11-07
Prokidney Corp expected to post a loss of 13 cents a share - Earnings Preview
ProKidney Announces Phase 3 Trial Progress for Rilparencel in Advanced CKD and Diabetes
Reuters  ·  11-07
ProKidney Announces Phase 3 Trial Progress for Rilparencel in Advanced CKD and Diabetes
ProKidney Presents Full Results From the Phase 2 Regen-007 Trial of Rilparencel at the American Society of Nephrology Kidney Week 2025
THOMSON REUTERS  ·  11-07
ProKidney Presents Full Results From the Phase 2 Regen-007 Trial of Rilparencel at the American Society of Nephrology Kidney Week 2025
ProKidney Corp. to Join Guggenheim Healthcare Innovation Conference
Reuters  ·  10-29
ProKidney Corp. to Join Guggenheim Healthcare Innovation Conference
BRIEF-Prokidney Corp to sell Greensboro property for $19.1 million - SEC filing
Reuters  ·  10-18
BRIEF-Prokidney Corp to sell Greensboro property for $19.1 million - SEC filing
ProKidney Corp - to Sell Greensboro Property for $19.1 Mln - SEC Filing
THOMSON REUTERS  ·  10-18
ProKidney Corp - to Sell Greensboro Property for $19.1 Mln - SEC Filing
Discovering Potential: IZEA Worldwide And 2 Other Top Penny Stocks
Simply Wall St.  ·  10-13
Discovering Potential: IZEA Worldwide And 2 Other Top Penny Stocks
SPAC King Chamath Palihapitiya Tells Retail Investors To Stay Away From His New SPAC
Benzinga_recent_news  ·  10-02
SPAC King Chamath Palihapitiya Tells Retail Investors To Stay Away From His New SPAC
ProKidney Leads Our Trio Of Promising Penny Stocks
Simply Wall St.  ·  09-12
ProKidney Leads Our Trio Of Promising Penny Stocks
ProKidney Corp. to Participate in Citi Biopharma Back to School and Morgan Stanley Global Healthcare Conferences
Reuters  ·  08-27
ProKidney Corp. to Participate in Citi Biopharma Back to School and Morgan Stanley Global Healthcare Conferences
ProKidney Q2 EPS $(0.13) Beats $(0.15) Estimate, Sales $221.000K
Benzinga  ·  08-13
ProKidney Q2 EPS $(0.13) Beats $(0.15) Estimate, Sales $221.000K
ProKidney Announces Positive Phase 2 REGEN-007 Results and FDA Alignment for Accelerated Approval Pathway of Rilparencel
Reuters  ·  08-13
ProKidney Announces Positive Phase 2 REGEN-007 Results and FDA Alignment for Accelerated Approval Pathway of Rilparencel

Introduction

Company Name.
ProKidney Corp.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease. ProKidney Corp. founded in 2015 and is headquartered in Winston-Salem, North Carolina.
Issue price:
--